Schwab Charles Investment Management Inc. Increases Holdings in Blueprint Medicines Corp (BPMC)

Schwab Charles Investment Management Inc. lifted its position in Blueprint Medicines Corp (NASDAQ:BPMC) by 8.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 168,835 shares of the biotechnology company’s stock after purchasing an additional 13,529 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.43% of Blueprint Medicines worth $11,763,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC boosted its position in Blueprint Medicines by 10.8% during the second quarter. FMR LLC now owns 5,300,589 shares of the biotechnology company’s stock valued at $268,581,000 after buying an additional 516,835 shares during the period. BlackRock Inc. boosted its position in Blueprint Medicines by 39.6% during the second quarter. BlackRock Inc. now owns 2,864,255 shares of the biotechnology company’s stock valued at $145,131,000 after buying an additional 811,820 shares during the period. Lord Abbett & CO. LLC boosted its holdings in shares of Blueprint Medicines by 0.5% during the second quarter. Lord Abbett & CO. LLC now owns 1,729,169 shares of the biotechnology company’s stock worth $87,617,000 after purchasing an additional 8,903 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Blueprint Medicines by 16.0% during the second quarter. Vanguard Group Inc. now owns 1,415,963 shares of the biotechnology company’s stock worth $71,746,000 after purchasing an additional 195,517 shares during the period. Finally, State Street Corp boosted its holdings in shares of Blueprint Medicines by 76.8% during the second quarter. State Street Corp now owns 1,400,035 shares of the biotechnology company’s stock worth $70,936,000 after purchasing an additional 608,296 shares during the period. 83.54% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Blueprint Medicines Corp (NASDAQ BPMC) opened at $78.45 on Friday. Blueprint Medicines Corp has a fifty-two week low of $30.98 and a fifty-two week high of $92.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.28 and a quick ratio of 11.28. The stock has a market cap of $3,300.00 and a P/E ratio of -22.94.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.06). The company had revenue of $8.07 million during the quarter, compared to analysts’ expectations of $5.35 million. Blueprint Medicines had a negative return on equity of 43.11% and a negative net margin of 437.83%. The company’s revenue for the quarter was up 31.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.62) EPS. analysts expect that Blueprint Medicines Corp will post -3.75 EPS for the current fiscal year.

Several analysts have commented on BPMC shares. Zacks Investment Research lowered shares of Blueprint Medicines from a “buy” rating to a “hold” rating in a report on Thursday. DA Davidson began coverage on shares of Blueprint Medicines in a report on Friday, September 29th. They issued a “buy” rating and a $90.00 price objective for the company. BTIG Research began coverage on shares of Blueprint Medicines in a research note on Friday, September 29th. They set a “buy” rating and a $90.00 target price for the company. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a research note on Tuesday, October 31st. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $79.00 target price (up previously from $64.00) on shares of Blueprint Medicines in a research note on Wednesday, September 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $84.10.

In related news, insider Anthony L. Boral sold 5,000 shares of Blueprint Medicines stock in a transaction on Monday, November 6th. The shares were sold at an average price of $70.40, for a total transaction of $352,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Marion Dorsch sold 18,334 shares of Blueprint Medicines stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $65.45, for a total transaction of $1,199,960.30. Following the transaction, the insider now owns 18,334 shares in the company, valued at approximately $1,199,960.30. The disclosure for this sale can be found here. Insiders have sold a total of 58,334 shares of company stock worth $3,978,160 in the last quarter. Corporate insiders own 3.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Schwab Charles Investment Management Inc. Increases Holdings in Blueprint Medicines Corp (BPMC)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/12/schwab-charles-investment-management-inc-increases-position-in-blueprint-medicines-corporation-bpmc.html.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply